摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-chloro-N-[2-(2-chloro-phenyl)-ethyl]-5-[4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide | 724423-90-9

中文名称
——
中文别名
——
英文名称
2-chloro-N-[2-(2-chloro-phenyl)-ethyl]-5-[4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide
英文别名
2-chloro-N-[2-(2-chlorophenyl)ethyl]-5-[4-(2-hydroxyethyl)-3,5-dioxo-1,2,4-triazin-2-yl]benzamide
2-chloro-N-[2-(2-chloro-phenyl)-ethyl]-5-[4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide化学式
CAS
724423-90-9
化学式
C20H18Cl2N4O4
mdl
——
分子量
449.293
InChiKey
XFAXEBSWHLTYJZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    30
  • 可旋转键数:
    7
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    102
  • 氢给体数:
    2
  • 氢受体数:
    5

文献信息

  • Combination therapies utilizing benzamide inhibitors of the P2X7 receptor
    申请人:Chung B. James
    公开号:US20060018904A1
    公开(公告)日:2006-01-26
    This invention provides methods of treatment of IL-1 mediated diseases comprising administering a pharmaceutically effective amount of a pharmaceutical agent selected from the group of sulfasalazine, a statin, a glucocorticoid agent, an inhibitor of p38 kinase, an anti-IL-6-receptor antibody, anakinra, an IL-1 monoclonal antibody, an inhibitor of JAK3 protein tyrosine kinase, a M-CSF monoclonal antibody or a humanized anti-CD20 monoclonal antibody and a benzamide inhibitor of the P2X 7 receptor of the formula: wherein R 1 -R 3 are as defined herein. The methods of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
    本发明提供了治疗IL-1介导疾病的方法,包括给予从磺胺嘧啶、他汀、糖皮质激素、p38激酶抑制剂、抗IL-6受体抗体、阿那西单抗、IL-1单克隆抗体、JAK3蛋白酪氨酸激酶抑制剂、M-CSF单克隆抗体或人源化的抗CD20单克隆抗体和P2X7受体苯甲酰胺抑制剂中选择的药物剂量。本发明的方法对于治疗IL-1介导的疾病非常有用,包括但不限于炎症性疾病如骨关节炎和类风湿性关节炎;过敏、哮喘、COPD、癌症、中风或心脏病的再灌注或缺血、自身免疫性疾病和其他疾病。
  • Benzamide inhibitors of the P2X, receptor
    申请人:Dombroski A. Mark
    公开号:US20060040939A1
    公开(公告)日:2006-02-23
    The present invention provides benzamide inhibitors of the P2X 7 receptor of the formula: wherein R 1 -R 3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
    本发明提供了P2X7受体的苯甲酰胺抑制剂,其化学式为:其中R1-R3的定义如本文所述。该发明的化合物在治疗IL-1介导的疾病方面有用,包括但不限于炎症性疾病,如骨关节炎和类风湿性关节炎;过敏、哮喘、慢性阻塞性肺疾病、癌症、脑卒中或心脏病的再灌注或缺血、自身免疫性疾病和其他疾病。
  • Benzamide inhibitors of the P2X7 receptor
    申请人:Pfizer Inc.
    公开号:US20040180894A1
    公开(公告)日:2004-09-16
    The present invention provides benzamide inhibitors of the P2X 7 receptor of the formula: 1 wherein R 1 -R 3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
    本发明提供了P2X7受体的苯甲酰胺抑制剂,其化学式为:1,其中R1-R3如本文所定义。本发明的化合物可用于治疗IL-1介导的疾病,包括但不限于炎症性疾病,如骨关节炎和类风湿性关节炎;过敏、哮喘、慢性阻塞性肺疾病、癌症、脑卒中或心脏病发作中的再灌注或缺血、自身免疫性疾病和其他疾病。
  • Benzamide Inhibitors of the P2X7 Receptor
    申请人:DOMBROSKI MARK A.
    公开号:US20090042886A1
    公开(公告)日:2009-02-12
    The present invention provides benzamide inhibitors of the P2X 7 receptor of the formula: wherein R 1 -R 3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
    本发明提供了P2X7受体的苯甲酰胺抑制剂,其化学式如下:其中R1-R3的定义如本文所述。该发明的化合物对于治疗IL-1介导的疾病有用,包括但不限于炎症性疾病,如骨关节炎和类风湿性关节炎;过敏、哮喘、慢性阻塞性肺疾病、癌症、脑卒中或心脏病发作中的再灌注或缺血、自身免疫性疾病和其他疾病。
  • Benzamide Inhibitors of The P2X7 Receptor
    申请人:Dombrowski A. Mark
    公开号:US20070281939A1
    公开(公告)日:2007-12-06
    The present invention provides benzamide inhibitors of the P2X 7 receptor of the formula: wherein R 1 -R 3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
    本发明提供了P2X7受体的苯甲酰胺抑制剂,其化学式如下:其中R1-R3的定义如本文所述。本发明的化合物可用于治疗IL-1介导的疾病,包括但不限于炎症性疾病,如骨关节炎和类风湿性关节炎;过敏,哮喘,慢性阻塞性肺疾病,癌症,中风或心脏病发作中的再灌注或缺血,自身免疫性疾病和其他疾病。
查看更多